Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 22 other studies
the abstract, start to end
… lower than glimepiride (risk ratio (RR) 0.15, 95%CI [0.10 to 0.22]).
… with canagliflozin (vs. placebo, RR 3.76, 95%CI [2.23 to 6.35]; vs. active comparators, RR 4.95, 95%CI [3.25 to 7.52]).
← favours treatmentfavours comparator →
could be chanceHypoglycaemia
RR 0.150.10–0.22
Adverse events & safety
RR 3.762.23–6.35
Adverse events & safety
RR 4.953.25–7.52
SGLT2 inhibitorsSulfonylureas & glinidesAdverse events & safetyHypoglycaemia
SGLT2 inhibitors × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
Sulfonylureas & glinides × hypoglycaemiaharms?one trial
unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
1 / 5